人类中多克索鲁比诱导心脏毒性的新目标和生物标志物:从毒基因组数据和分子建模中得出的含义
相关实验视频
Updated: Jul 5, 2026

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.7K
Fuat Karakuş1, Abdulilah Ece2, Burak Kuzu3
1Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Van Yuzuncu Yil University, Van, Türkiye.
Journal of biomolecular structure & dynamics
|November 14, 2024
概括
doxorubicin 的心脏毒性导致不可逆转的心力衰竭. 这项研究确定了关键的分子机制和代谢物,包括7-deoxidoxorubicinone,有助于慢性多克索鲁比辛心脏毒性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 心血管医学 心血管医学
背景情况:
- 多克索鲁比化疗会导致危及生命的心脏毒性.
- 慢性多克索鲁比心脏毒性是不可逆转的,导致扩张性心肌病和心力衰竭.
- 了解多克索鲁比代谢物的分子机制至关重要.
研究的目的:
- 确定多克索鲁比代谢物在多克索鲁比诱导的慢性心脏毒性中的分子机制.
- 调查特定多克索鲁比代谢物在心力衰竭中的作用.
- 发现关键的基因,转录因子和涉及心脏毒性的微RNA.
主要方法:
- 使用多个数据库和工具进行文献搜索和in silico毒基因组学分析.
- 使用施罗丁格软件进行了分子动力学模拟.
- 在人类心脏中识别多克索鲁比代谢物及其向基因.
主要成果:
- 在人心中,多克索鲁比转化为五种代谢物.
- 十一个常见的基因将多克索鲁比辛,其代谢物,扩张性心肌病和心力衰竭联系在一起.
- 多克索鲁比及其代谢产物与β-1上腺素受体和脂肪酸合成酶结合.
- 确定了关键的转录因子 (Nkx-2.6) 和微RNA (hsa-miR-183-3p).
- 7-deoxidoxorubicinone,与多克索鲁比醇一起,可能会导致心脏毒性.
结论:
- 多克索鲁比代谢产物在慢性心脏毒性中起着重要作用.
- 已经确定了特定的分子标和调节因素.
- 这些发现有助于更好地理解多克索鲁比诱导的心力衰竭机制.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

